AzTrials
AzTrials

Cardiac CatheterizationKETADEXNCT07564531

Efficacy and Safety of a Combined Dexmedetomidine-Ketamine Sedation Regimen for Pediatric Cardiac Catheterization

An observational study of Cardiac Catheterization and Pediatric, run by National Children's Hospital, Vietnam at 1 site in Vietnam.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to learn if the spontaneous sedation regimen of dexmedetomidine-ketamine (KETADEX) has the comparable efficacy and safety in pediatric cardiac catheterization versus the traditional regimen. Read more about this study

Who is it for?
Ages Up to 18 years
Conditions the study is for
Cardiac Catheterization, Pediatric
What is being tested?
Spontaneous sedation regimen and General anesthesia regimen
How many people
150 participants
Where
1 siteVietnam
Study dates
4 Feb 2026to 30 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Pediatric patients undergoing cardiac catheterization at Vietnam National Children's Hospital

Who may be able to join

  • Patients under 18 years of age.
  • Patients indicated for diagnostic or interventional cardiac catheterization.

Who cannot join

  • Patients with acute respiratory infections, chromosomal abnormalities, metabolic disorders, or other co-existing medical conditions.
  • Arrhythmias, second- or third-degree atrioventricular (AV) block; patients on mechanical ventilation or requiring vasopressors prior to the procedure.
  • Known history of allergy or hypersensitivity to dexmedetomidine, ketamine, propofol, midazolam, or sevoflurane.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Hong Ha Thi Nguyen, PhD contact

+84904111838

honghant@nch.gov.vn

Nhat Minh Tran, BPharm, MSc contact

+84936110303

nhatminh@nch.gov.vn

Vietnam1 site, 1 recruiting
  • Vietnam National Children's Hospital

    Hanoi, 10000

    Hong Ha Thi Nguyen, PhD., +84904111838, honghant@nch.gov.vn

    Nhat Minh Tran, BPharm, MSc, +84936110303, nhatminh@nch.gov.vn

    Recruiting

Other trials in Vietnam

About this study

Official title: Evaluation of the Efficacy and Safety of a Combined Dexmedetomidine-Ketamine Sedation Regimen for Pediatric Cardiac Catheterization at Vietnam National Children's Hospital

The goal of this observational study is to learn if the spontaneous sedation regimen of dexmedetomidine-ketamine (KETADEX) has the comparable efficacy and safety in pediatric cardiac catheterization versus the traditional regimen. The main question it aims to answer is:

Is the combined Dexmedetomidine-Ketamine spontaneous sedation regimen (KETADEX) non-inferior to the traditional general anesthesia regimen in terms of efficacy and safety?

Participants would received either KETADEX regimen or general anesthesia regimen. Research members then observe the catheterization procedure and answer the questionnaire about their efficacy and safety.

Being tested
Spontaneous sedation regimen, General anesthesia regimen
Keywords
dexmedetomidine, ketamine, spontaneous sedation, general anesthesia, cardiac catheterization

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spontaneous sedation regimenDrug

    Patients who are naturally ventilated, undergo spontaneous sedation regimen including: dexmedetomidine and ketamine.

  • General anesthesia regimenDrug

    Patients who are mechanically ventilated, undergo general anesthesia regimen

Study groups in NCT07564531
Study groupRoleWhat they receive
KETADEXPediatric patients undergoing the dexmedetomidine-ketamine spontaneous sedation regimen on cardiac catheterization
Receives: Drug: Spontaneous sedation regimen
GAPediatric patients undergoing the traditional general anesthesia regimen on cardiac catheterization
Receives: Drug: General anesthesia regimen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The rate of achieving Ramsay Sedation Scale score 6 without the need for rescue anesthesia and the occurrence of any adverse events throughout the duration of the cardiac catheterization procedure.

    The primary endpoint is the rate of achieving the sedation target, which is Ramsay Sedation Scale score of 6, without the need for rescue anesthesia and without any adverse events in cardiovascular, respiratory, or neurological systems occurred during the anesthesia/sedation induction, cardiac catheterization, and recovery periods.

    Measured: Perioperative/periprocedural

Secondary outcomes (5)
  1. Incidence of respiratory adverse events throughout the duration of the cardiac catheterization procedure

    Incidence of respiratory adverse events throughout the cardiac catheterization procedure (sedation/anesthesia induction, cardiac catheterization, and recovery periods) including:

    • Oxygen desaturation: SpO2 decreased > 10% below the lower limit of the normal ranges expressed in percent (%)
    • Respiratory Rate Change: An increase or decrease in respiratory rate by > 20% compared to pre-sedation levels.
    • Increased Lactate: Lactate level > 2 mmol/L after the procedure (only if lactate level before procedure is ≤ 2 mmol/L), expressed in mmol/L.
    • Hypercapnia: PaCO2 > 45 mmHg after the procedure (only if PaCO2 level before procedure is ≤ 45 mmHg), expressed in mmHg.
    • Increased Secretions: Based on clinical observation throughout the procedure, expressed in "yes" or "no".

    Measured: Perioperative/periprocedural

  2. Incidence of cardiovascular adverse events throughout the duration of the cardiac catheterization procedure

    Incidence of cardiovascular adverse events throughout the cardiac catheterization procedure (sedation/anesthesia induction, cardiac catheterization, and recovery periods):

    • The presence of bradycardia: Based on age-adjusted criteria, bradycardia was defined as a HR <20% below the lower limit of the normal ranges expressed in beats/min
    • The presence of tachycardia: Based on age-adjusted criteria, tachycardia was defined as a HR > 20% above the upper limit of the normal ranges expressed in beats/min
    • The presence of hypertension: Based on age-adjusted criteria hypertension was defined as a MAP >20% above the upper limit of the normal ranges expressed in mmHg
    • The presence of hypotension: Based on age-adjusted criteria hypertension was defined as a MAP <20% below the lower limit of the normal ranges expressed in mmHg

    Measured: Perioperative/periprocedural

  3. Incidence of neurological adverse events throughout the recovery period.

    Incidence of neurological adverse events during recovery from the procedure:

    • The presence of Nausea and/or Vomiting: defined as the occurrence of nausea and vomitting observed clinically, expressed in "yes" or "no".
    • The presence of Emergence Agitation and/or Post-Anesthetic Shivering: defined as the occurrence of Emergence Agitation and/or Post-Anesthetic Shivering observed clinically, expressed in "yes" or "no".

    Measured: Up to 3 hours post-procedural

  4. Incidence of any of the adverse events during the use of the sedation and anesthesia regimen

    Any of the respiratory and cardiovascular events during the use of the sedation and anesthesia regimen that are considered not related to pain reaction.

    Measured: From sedation initiation to the end of the procedure

  5. Incidence of any of the adverse events during the recovery from the procedure

    Any of the adverse events during recovery from the procedure.

    Measured: Up to 3 hours post-procedural

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 May 2026
  2. Study start4 Feb 2026
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07564531
Sponsor's protocol ID
2026S-07
Acronym
KETADEX
Status last verified
Mar 2026
First submitted
17 Mar 2026
Last updated
4 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Mikus M, Welchowski T, Schindler E, Schneider M, Mini N, Vergnat M. Sedation versus General Anesthesia for Cardiac Catheterization in Infants: A Retrospective, Monocentric, Cohort Evaluation. J Clin Med. 2021 Nov 30;10(23):5648. doi: 10.3390/jcm10235648.

    PubMed 34884350
  • Hằng, N. T. T., Nam, Đỗ V., Hà, N. T. N., Minh, Đỗ T., Trang, H. T. T., Anh, N. T. V., Huệ, V. T. ., Anh, N. N., Phúc, N. X., & Tuyên, H. N. (2024). 1. KẾT HỢP DEXMEDETOMIDINE VÀ KETAMIN ĐỂ AN THẦN TỰ THỞ CHO BỆNH NHÂN NHI ĐANG THỰC HIỆN THÔNG TIM: KẾT QUẢ BAN ĐẦU TẠI BỆNH VIỆN NHI TRUNG ƯƠNG VIỆT NAM. Tạp Chí Y học Cộng đồng, 65(CĐ 9 - Hội Gây mê Hồi sức). https://doi.org/10.52163/yhc.v65iCD9.1506

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiac Catheterization and Pediatric, run by National Children's Hospital, Vietnam at 1 site in Vietnam.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hong Ha Thi Nguyen, PhD (+84904111838, honghant@nch.gov.vn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The rate of achieving Ramsay Sedation Scale score 6 without the need for rescue anesthesia and the occurrence of any adverse events throughout the duration of the cardiac catheterization procedure. (time frame: Perioperative/periprocedural). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07564531, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in